• November 16, 2017

This article lays the groundwork for a re-think concerning the ways in which the patient or caregiver is intended to use OIPs and related devices. A case is made for advocating an approach by all stakeholders in the OIP life-cycle that ultimately results in simple-to-use and “patient-friendly” OIPs and related devices that will prove to […]

AIM: Proof of Concept The present version of the Abbreviated Impactor Measurement (AIM) Concept was born three years ago, initially as a way of improving productivity in the course of making in vitro measurements of Oral Inhaled Products (OIPs) and related add-on devices, such as spacers and valved holding chambers that are used with pressurized […]

Nasal sprays are now showing great promise in the delivery of drugs for breakthrough pain relief and vaccines. Innovation is set to continue as electronic “smart” devices are being integrated into designs in order to increase patient compliance, a key market driver for nasal aerosols.

  • November 1, 2017

Spray pattern and plume geometry have long been established as required tests for orally inhaled and nasal drug product (OINDP) characterization. Furthermore, these tests are important indicators of aerosolization, spray performance and subsequent bioavailability (BA) of the delivered drug.

Over the last 20 years, inhalation drug delivery has been adjusting to the phase out of chlorofluorocarbon (CFC) propellants. Following the signature of the Montreal Protocol on September 16, 1987, there has been a rush to re-formulate pressure metered dose inhalers (pMDIs) using alternative propellant systems. This has led to the advent of dry powder […]